Publications

Detailed Information

Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand on the Reduction of Joint Inflammation in Experimental Rheumatoid Arthritis

DC Field Value Language
dc.contributor.authorJin, Cheng-Hao-
dc.contributor.authorChae, Su Young-
dc.contributor.authorKim, Tae Hyung-
dc.contributor.authorYang, Han-Kwang-
dc.contributor.authorSong, Yeong Wook-
dc.contributor.authorLee, Kang Choon-
dc.contributor.authorJo, Dong-Gyu-
dc.contributor.authorLee, Eun Young-
dc.date.accessioned2012-06-26T04:56:24Z-
dc.date.available2012-06-26T04:56:24Z-
dc.date.issued2010-03-
dc.identifier.citationJOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS; Vol.332 3; 858-865ko_KR
dc.identifier.issn0022-3565-
dc.identifier.urihttps://hdl.handle.net/10371/77423-
dc.description.abstractThis study focused on the potential therapeutic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on collagen-induced arthritis (CIA) and on the elucidation of the mechanisms involved. DBA/1J mice with established CIA were treated with various amount of recombinant soluble human TRAIL. The effects of TRAIL on the development and severity of CIA in this DBA/1J mouse model were assessed clinically and histologically, and a detailed investigation was conducted on proinflammatory cytokine and anticollagen-specific antibody levels. Cellular immunity was evaluated by investigating the proliferative responses and cytokine release profiles of splenocytes after TRAIL treatment. TRAIL treatment significantly reduced the severity and incidence of CIA, joint swelling, erythema, and edema. Histologic evaluations revealed that inflammatory cell infiltration, cartilage destruction, and bone erosion were significantly reduced in joints of TRAIL-treated mice with dose-dependent manner. TRAIL treatment also strongly decreased and/or normalized the productions of proinflammatory cytokines and of anti-collagen-specific antibodies in the sera of CIA mice. Furthermore, in vitro studies with primary splenocytes showed the cytotoxic effect of TRAIL on activated lymphocytes, with reduction of inflammatory cytokine release. These findings show that TRAIL administration is an effective anti-inflammatory treatment that prevents the development and progression of CIA in DBA/1J mice, and they suggest that TRAIL might be considered a potential treatment for human RA.ko_KR
dc.language.isoenko_KR
dc.publisherAMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSko_KR
dc.titleEffect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand on the Reduction of Joint Inflammation in Experimental Rheumatoid Arthritisko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor채수영-
dc.contributor.AlternativeAuthor김태형-
dc.contributor.AlternativeAuthor양한광-
dc.contributor.AlternativeAuthor이은영-
dc.contributor.AlternativeAuthor송영욱-
dc.contributor.AlternativeAuthor조동규-
dc.contributor.AlternativeAuthor이강춘-
dc.identifier.doi10.1124/jpet.109.159517-
dc.citation.journaltitleJOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS-
dc.description.citedreferenceYoun YS, 2007, BIOTECHNOL LETT, V29, P713, DOI 10.1007/s10529-006-9300-7-
dc.description.citedreferenceMartinez-Lorenzo MJ, 2007, CLIN IMMUNOL, V122, P28, DOI 10.1016/j.clim.2006.07.007-
dc.description.citedreferenceYao QP, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1867-
dc.description.citedreferenceBorchers AT, 2004, SEMIN ARTHRITIS RHEU, V34, P465, DOI 10.1016/j.semarthrit.2003.12.003-
dc.description.citedreferenceEvans CH, 2004, GENE THER, V11, P735, DOI 10.1038/sj.gt.3302256-
dc.description.citedreferenceLi EK, 2004, CLIN THER, V26, P447-
dc.description.citedreferenceLiu ZG, 2003, J CLIN INVEST, V112, P1332, DOI 10.1172/JCI2003219209-
dc.description.citedreferenceTsokos GC, 2003, J CLIN INVEST, V112, P1315, DOI 10.1172/JCI200320297-
dc.description.citedreferenceBrand DD, 2003, SPRINGER SEMIN IMMUN, V25, P3, DOI 10.1007/s00281-003-0127-1-
dc.description.citedreferenceLamhamedi-Cherradi SE, 2003, NAT IMMUNOL, V4, P255, DOI 10.1038/ni894-
dc.description.citedreferenceMackay F, 2002, CURR OPIN IMMUNOL, V14, P783-
dc.description.citedreferenceGenovese MC, 2002, ARTHRITIS RHEUM, V46, P1443, DOI 10.1002/art.10308-
dc.description.citedreferenceLunemann JD, 2002, J IMMUNOL, V168, P4881-
dc.description.citedreferenceLuross JA, 2001, IMMUNOLOGY, V103, P407-
dc.description.citedreferenceLipsky PE, 2000, NEW ENGL J MED, V343, P1594-
dc.description.citedreferenceSong KM, 2000, J EXP MED, V191, P1095-
dc.description.citedreferenceAshkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255-
dc.description.citedreferenceGriffith TS, 1998, CURR OPIN IMMUNOL, V10, P559-
dc.description.citedreferenceAshkenazi A, 1998, SCIENCE, V281, P1305-
dc.description.citedreferenceEmery JG, 1998, J BIOL CHEM, V273, P14363-
dc.description.citedreferenceMarsters SA, 1997, CURR BIOL, V7, P1003-
dc.description.citedreferenceChaudhary PM, 1997, IMMUNITY, V7, P821-
dc.description.citedreferenceWalczak H, 1997, EMBO J, V16, P5386-
dc.description.citedreferenceCohen GM, 1997, BIOCHEM J, V326, P1-
dc.description.citedreferencePan GH, 1997, SCIENCE, V277, P815-
dc.description.citedreferenceGura T, 1997, SCIENCE, V277, P768-
dc.description.citedreferencePan GH, 1997, SCIENCE, V276, P111-
dc.description.citedreferenceCampion GV, 1996, ARTHRITIS RHEUM, V39, P1092-
dc.description.citedreferenceFeldmann M, 1996, CELL, V85, P307-
dc.description.citedreferenceSmolen JS, 1996, SCAND J RHEUMATOL, V25, P1-
dc.description.citedreferenceWiley SR, 1995, IMMUNITY, V3, P673-
dc.description.citedreferenceSCHNABEL A, 1994, SEMIN ARTHRITIS RHEU, V23, P310-
dc.description.citedreferencePANAYI GS, 1992, ARTHRITIS RHEUM, V35, P729-
dc.description.citedreferenceFIRESTEIN GS, 1990, ARTHRITIS RHEUM, V33, P768-
dc.description.citedreferenceHARRIS ED, 1990, NEW ENGL J MED, V322, P1277-
dc.description.tc1-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share